Home / About us / Leadership / Amanda Mullen, BSc, MBA
Amanda Mullen, BSc, MBA
Chief Operating Officer
Amanda received her Bachelor of Science in Biology and Business from Dalhousie University and her Master of Business Administration in Innovation Leadership from the University of Fredericton.
Amanda was the first employee and co-founder of AGADA. Prior to starting AGADA, she worked as a researcher for ReveraGen BioPharma, a biotech company developing therapeutics for neuromuscular and inflammatory diseases. Amanda oversees preclinical and clinical operations while managing business systems, business development, and resources.
As Chief Operations Officer, Amanda provides strategic oversight of AGADA’s day-to-day operations, ensuring the seamless delivery of high-quality services to clients. She leads cross functional departments, drives operational excellence through continuous improvement, and oversees resource planning, quality systems and organizational performance. Working closely with the executive team, Amanda helps shape and execute AGADA’s strategic vision while fostering a collaborative, client-focused cuture that supports scientific innovation and growth.
Get in touch
To learn how AGADA Biosciences could support your program, get in touch with our team and start the conversation.
How we work
We bring an agile, collaborative and responsive approach to every engagement, shaping our support around the needs of your program rather than a rigid process. Whether you engage us at a single stage or across multiple points in development, we work to de-risk programs, protect data integrity and help your teams progress with confidence.
1
Refined for your program:
We shape our approach around the needs of each program, not the other way around.
2
Direct access to senior experts:
Our lean model keeps scientific expertise close to the work and communication clear.
3
Built to de-risk progress:
We help you de-risk development through rigorous science and practical support.
4
Protecting data integrity:
Our work is designed to support reliable outputs and maintain confidence in the data.
Why AGADA?
We bring dedicated expertise to programs where there is little room for error, providing the scientific support, responsiveness and program fit that help rare disease teams move forward with clarity.
Decade of specialization:
Founded in 2013 as a spinout from Children’s National Medical Center to provide specialist scientific support for rare disease drug development.
Consistent audit success:
We successfully pass an average of five sponsor audits annually to support clinical trials across multiple phases.
Historical benchmarking:
We leverage archival data from over 100 trials in mouse models of muscular dystrophy to accurately power your efficacy studies.
Dedicated scale:
We operate with a team of approximately 50 employees, entirely focused on executing complex rare disease programs.
Meet more of the leadership team
